GlassScriptPhysician profile
Farid Azizollahi
NPI 1649328519
$7,923.61
in general payments reported to CMS, 2019-2025
48 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,170 · 2020: $313 · 2021: $714 · 2022: $1,584 · 2023: $1,585 · 2024: $1,676 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,129 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,128.70 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,255.72 | 2019-2025 | Ubrelvy, Vraylar, Viberzi |
| Astrazeneca Pharmaceuticals LP | $698.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $567.25 | 2019-2025 | Prolia, Evenity, Otezla |
| Janssen Pharmaceuticals, INC | $453.79 | 2019-2024 | Spravato |
| Lilly USA, LLC | $428.18 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.01 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $409.78 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.62 | 2019-2024 | Xifaxan |
| Astellas Pharma US INC | $356.71 | 2019-2022 | |
| Pfizer INC. | $245.75 | 2019-2024 | |
| Amarin Pharma, INC. | $232.29 | 2019-2023 | |
| Allergan, INC. | $189.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $176.40 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $165.80 | 2023-2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $155.63 | 2021-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farid Azizollahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.